Baidu
map

Medicine:头颈部肿瘤患者放射治疗时,警惕发生痴呆

2015-12-31 phylis 译 MedSci原创

头颈部癌患者进行手术、放疗、化疗(CT)。以前观察到这些患者存在颈动脉损伤和神经毒性。这项研究估计头部和颈部癌症患者不同治疗后,老年痴呆症发生的风险。分析台湾的国家健康保险索赔数据库和癌症登记数据库中的数据。研究包括2002年1月1日至2010年12月31日进行治疗的头颈部癌患者。随访时间从指数日期至2012年12月31日。纳入标准为头颈部肿瘤;年龄>20岁;并接受手术、化疗、并行化疗或手术辅助治

头颈部癌患者进行手术、放疗、化疗(CT)。以前观察到这些患者存在颈动脉损伤和神经毒性。这项研究估计头部和颈部癌症患者不同治疗后,老年痴呆症发生的风险。

分析台湾的国家健康保险索赔数据库和癌症登记数据库中的数据。研究包括2002年1月1日至2010年12月31日进行治疗的头颈部癌患者。随访时间从指数日期至2012年12月31日。纳入标准为头颈部肿瘤;年龄>20岁;并接受手术、化疗、并行化疗或手术辅助治疗。排除标准为:头颈部癌症诊断前有其他肿瘤或头颈癌症治疗后2年内诊断为痴呆;指数日期前发生卒中;远处转移,原位癌,肉瘤,头部和颈部癌症复发,未知的性别和年龄<20岁。

共有20135例患者。患者单纯手术治疗,手术和放化疗联合治疗及放化疗治疗,老年痴呆症的发病率(每1000人年)分别为1.44,1.04和1.98。放疗联合化疗治疗或单独放疗治疗的患者,痴呆发生的原始HR值为1.84(95%CI: 1.21-2.81)。校正年龄,性别,临床分期及共发病后,HR为1.92(95% CI:1.14-3.24)。根据Cox比例风险模型显示,年龄大于65岁,进行RT联合CT或单独RT治疗是痴呆发生的风险因素(HR值分别为:16.5和1.92)。不同治疗组中,不同临床分期的患者,痴呆发生的风险没有显著差异。然而,接受RT联合治疗或单独RT治疗的年轻患者(年龄小于65岁),发生痴呆的风险分别是单独手术治疗发生风险的2.96倍(95% CI 1.24-7.08)和 3.54倍(95% CI 1.32-9.51)。接受总辐射剂量>6660 cGy的患者发生痴呆的风险是接受总辐射剂量<6660 cGy的1.69倍(95% CI 0.97-2.95)。接受高剂量的辐射增加痴呆发生的风险,并且这个风险持续到RT进行后9年。

RT后,年轻患者(小于65岁)发生痴呆的风险较高。年轻患者进行颈部或接近脑组织的区域放射治疗时,注意放射剂量的选择,尤其是台湾地区,这个地方患者头颈部肿瘤的发病的平均年龄为53岁。

原文出处:

Chen JH, Yen YC, et al. Dementia Risk in Irradiated Patients With Head and Neck Cancer. Medicine (Baltimore). 2015 Nov.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-12-08 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-09-01 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-01-04 wzf990214

    有意思

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-01-04 wzf990214

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-01-02 cjingjuan

    \(≧▽≦)/赞

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
    2016-01-02 wshxjq
  8. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1858648, encodeId=43f71858648d3, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Dec 08 02:29:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773522, encodeId=98aa1e73522ae, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Sep 01 05:29:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51622, encodeId=8157516223f, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51623, encodeId=b8435162302, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Jan 04 06:57:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51248, encodeId=c09751248e4, content=\(≧▽≦)/赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3865018, createdName=cjingjuan, createdTime=Sat Jan 02 19:43:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424151, encodeId=74d11424151aa, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491767, encodeId=9a4e1491e675f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577452, encodeId=6b4915e74521f, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589691, encodeId=ed0b15896916c, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606791, encodeId=26ae1606e9184, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jan 02 05:29:00 CST 2016, time=2016-01-02, status=1, ipAttribution=)]

相关资讯

Radiother Oncol:功能影像学改变能预测晚期头颈部肿瘤患者对诱导化疗反应

在头颈部肿瘤患者进行放化疗前首先进行诱导化疗时,功能影像能反映患者对最优治疗计划的适应性。因此,理解诱导化疗对功能影像的影响是必要的。为了前瞻性的评估获得序列 FI(18F-FDG-PET, 弥散加权(DW)和动态对比增强(DCE) MRI)的可行性以及其在确定头颈部肿瘤患者诱导化疗后个体治疗方案中的作用。为了解答上述问题,Ceri Powell等进行了相关研究,研究结果发表在Radiother

JAMA OHNS:烟酒或延长头颈部肿瘤患者留置胃管时间

JAMA Otolaryngology-Head & Neck Surgery最新在线发表的一项研究报告显示,吸烟和过量饮酒的将可能成为头颈部肿瘤患者接受放疗或化疗放置胃管时间延长的危险因素之一。该研究的背景介绍指出,对于晚期头颈部肿瘤患者而言,放化疗是一个行之有效的治疗方法。然而,放化疗相应带来的毒副性作用则将降低食欲进而引起体重下降和营养不良。因此,许多机构推荐在患者接受放化疗之前预防

CSCO 2014:唐平章头颈肿瘤论坛,望再创高峰

头颈肿瘤论坛负责人、中国医学科学院肿瘤医院  唐平章 今年CSCO年会中的头颈肿瘤论坛主要分为两个部分,分别为各高端专家进行发言的主题报告和由青年学者进行发言的论文交流。 高端专家引领继续教育 专家主题报告中,中国医学科学院肿瘤医院唐平章教授将进行头颈鳞癌颈清扫术进展的介绍,内容主要涉及近年来头颈肿瘤手术技术的发展,颈清扫已由过去的大面积切除转为如今的保留颈部肌肉丰满度等精细操

Oral Oncol:不刷牙,小心头颈癌找上你

头颈癌(HNC)是指发生在口腔、咽喉、鼻窦、喉部、头骨基部以及头部的恶性肿瘤,是世界上第六好发癌症,其治疗难度较大。因此,了解HNC发生的任何有关因素都很重要,吸烟和喝酒是已确定的危险因素,而且是HNC发生的主要病因。其他的危险因素包括遗传因素、人类乳头瘤病毒(HPV)感染、牙周病、牙齿丧失、口腔卫生较差、较差的牙齿状态等在HNC的发生中也有作用。牙菌

2014年第一版NCCN头颈部肿瘤指南更新要点简介

美国国家综合癌症网络(NCCN)指南是目前国际上应用最广泛的肿瘤学临床指南之一。近期,NCCN发布了2014年第一版头颈部肿瘤临床实践指南,该指南与2013年第二版相比,诊治原则方面仅在细节上进行了部分修订。本文主要对新版NCCN头颈部肿瘤指南外科治疗及放化疗方面的更新进行解读,希望能为临床医生深入理解和应用该指南提供帮助。头颈部肿瘤外科手术治疗方面的更新对临床未发现肿大淋巴结的口腔癌患者是否需要

FMISO PET/CT可以用于预测晚期头颈部肿瘤患者预后

  为了探究局部晚期头颈部肿瘤患者在接受放化疗前和放化疗过程中低氧影像的预后预测价值,Daniel Zips等设计了一项前瞻性研究,研究结果发表在Radiother Oncol 10月刊上。   有25名III/IV期头颈部肿瘤患者被纳入研究,采用[18F]-fluoromisonidazole (FMISO) PET/CT在放化疗过程中的

Baidu
map
Baidu
map
Baidu
map